

# PolyPhil™ eye

Injectable Polynucleotides

## Minimally invasive aesthetic treatment for reviving tired looking eyes

### Indicated areas:<sup>1</sup>

- Eye contour area<sup>1</sup>
- Sensitive skin and delicate areas<sup>1-2</sup>


### Purpose:

**#1** A standalone treatment to hydrate the extracellular matrix and fill the depressed dermal spaces in the periocular area with skin quality problems<sup>4</sup>


**SET** Skin Enhancement Technique (SET) generates a synergistic effect and helps prepare the skin before other aesthetic procedures: laser, energy and light-emitting devices, filler, peeling, needling and surgery<sup>3</sup>.

### Injection protocol and injection technique:<sup>2</sup>

Treatment	Suggested protocol	Injection technique
Improvement of skin quality and hydrating the periocular region	One session (1-2 ml) every 14 or 21 days for a total of 3-4 sessions.  <b>Suggested maintenance:</b> one session every 1-2 months or, as an alternative, 2-3 complete three-session intradermal treatment cycles per year.	Intradermal injection  Needle microdroplet  Linear retrograde



### Around the eye and delicate areas



**Concentration:** 15 mg/2 ml | **Pack:** 1 x 2 ml pre-filled syringe  
**Needle:** 2 x 30G x 1/2, 13 mm | **Depth of injection:** intradermal

# Excellent value and safety in improving skin quality in the periocular region<sup>4</sup>

The earliest signs of ageing tend to appear in the periocular area, caused mainly by the **loss and redistribution of volume and bone resorption**. This area of skin is **extremely thin and sensitive** and can be prone to adverse reactions such as bruising and swelling.


## PolyPhil eye has been developed for this delicate area.

- Contributes to a vital and optimal physiological environment.
- Promotion of the filling of depressed intradermal spaces.
- The long-term outcome is supporting and promoting the dermal fibroblast viability and a sound extracellular matrix environment in the dermis of lids, tear troughs, and other hollow and atrophic periocular areas.


## Real world experience

- Observational survey to further **confirm the efficacy and safety of PolyPhil eye**
- Subjects undergone a **3-sessions treatment cycle** with 15 mg/2 ml PolyPhil eye in the periocular district
- Objective **periocular skin-quality improvement** based on the WSRS<sup>†</sup>
- Improvement, assessed objectively and subjectively, of overall facial appearance based on the GAIS<sup>††</sup>

<sup>†</sup>WSRS: Wrinkle Severity Rating Scale; <sup>††</sup>GAIS: Global Aesthetic Improvement Scale



Comparison of the mean WSRS scores for periocular and facial wrinkles and skin quality at the baseline and the final follow-up visits for all cohort subjects and outpatients. \*\* p <0.001 vs baseline.



Comparison of the overall severity of periocular areas at the baseline and final follow-up visits (WSRS severity descriptors) in the 48 surveyed subjects and outpatients. Overall improvement in the distribution of severity: p <0.001.

PolyPhil eye retains its usual efficacy in the periocular region with no variations over time and no differences in subjects and outpatients with still correctly structured and hypotrophic skin. Safety of use in the delicate periocular areas is also consistently excellent.

**1** IFU PolyPhil eye | **2** Cavallini M, Bartoletti E, Maioli L, Massironi A, Pia Palmieri I, Papagni M et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine. *J Cosmet Dermatol*. 2021 Mar;20(3):922-928. doi: 10.1111/jocd.13679. Epub 2020 Sep 21. PMID: 32799391; PMCID: PMC7984045. | **3** Cavallini M, Papagni M. Long Chain Polynucleotides Gel and Skin Biorevitalization. *International Journal of Plastic Dermatology-ISPLAD*. 2007; 3(3): 27-32. | **4** Palmieri IP et al. An Innovative PN HPT™-based Medical Device for the Therapy of Deteriorated Periocular Skin Quality. *Surg Res*. 2023; 5(2): 1-7. / **CE** 0373

The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.